New Concepts in Glaucoma » Glaucoma Research and Clinical Advances 2018 to 2020

Glaucoma Research and Clinical Advances

Volume 2 - 2018 to 2020

ISBN: 978-90-6299-271-3

Editors:

John R. Samples
Paul A. Knepper

Volume 2 of the Glaucoma Research and Clinical Advances series continues our desire to address glaucoma with a combination of science and speculation. As science expands, the emphasis is on data, interpretation, and dogma. We disagree; open minds open new approaches. Using methodologies that are primarily molecular and genetic, we seek to refine the causes of glaucoma as well as how it is best treated, especially incorporating thoughts and hypotheses about new methods of treatment. Glaucoma is a complex disease, and genetics proves that a variety of proteins are culpable at one level. At another level, however, there are likely final common pathways and numerous feedback loops which have defied explanations to date.

The search for answers goes on in basic science researcher’s laboratories and clinical ophthalmologist’s offices and operating rooms. We are all well-served by understanding that glaucoma is a neurodegenerative disease. Current attempts to solve the disease have focused on two strategic arenas:

the trabecular meshwork function and its impact on intraocular pressure as a major risk factor for the disease; and
the optic nerve dysfunction leading to visual loss.

Genetic mutations have yielded puzzling clues to the cause, but without resolution. For example, mutations in myocilin and optineurin genes are closely connected to the phenotype, but how do they cause the disease? In the next two years, priority areas of research are signaling pathway discoveries, biomarker panels, epigenetic factors, and continued genomic studies to yield answers to the common final pathways of the disease.

The final pathways are complex and redundant, such that the overlap of bio-informatics will be challenging. Current promising leads suggest the innate immune system holds important clues to both trabecular meshwork and optic nerve pathophysiology. When the primary open-angle glaucoma disease pathways are unraveled, drug discoveries and new treatment modalities will be available for better regulation of intraocular pressure and neuroprotection for the optic nerve. This volume discusses the glaucoma pipeline from several perspectives as well as future candidate classes. As always, the authors herein are urged to speculate on how the cure of glaucomatous optic nerve damage will yield to new treatments.

Volumes in the Glaucoma Research and Clinical Advances series:

Table of Contents

Preliminary Table of Contents – Volume 2

Science insights

Do you hear me now? Mechanisms of cellular communication in the trabecular meshwork – Kate E. Keller

The innate immune system in primary open-angle glaucoma – Paul A. Knepper, Nicholas M. Pfahler, Kevin Carey, Indre Bielskus

Phagocytic activity in the trabecular meshwork – Paloma B. Liton

How fibronectin fibrillogenesis can regulate aqueous humor outflow – Jennifer A. Faralli, Jennifer Peotter, Donna M. Peters

Cell-derived matrices as a model to study ocular hypertension – VijayKrishna Raghunathan

Bioengineered human trabecular meshwork membrane constructs: opportunities and challenges – Karen Y. Torrejon, Matthew D. Kerr

Is there a final common pathway affected in POAG? – Brian S. McKay, R. Rand Allingham and W. Daniel Stamer

Clinical

Trabecular Stem cell: review and speculation – Tin Aung et al.

Genetics of POAG in Greece – Anastasios G. P. Konstas, John R. Samples, Mary K. Wirtz

Blood flow parameters of the optic nerve – Priyanka Parekh, Alon Harris, Josh Gross, Brent Siesky

Systemic manifestations of microvascular disease in primary open-angle – Nicholas M. Pfahler, Michael M. Miazga, Indre Bielskus, Elani Kaufman, Jack G. McGuire, Thomas Cronin, Ryan McCarthy, Michael C. Giovingo, Nicholas J. Volpe, Angelo P. Tanna, Louis R. Pasquale, Paul A. Knepper

Imaging of the narrow angle – Marisse Masis, Shan C. Lin

Medications

The link between Alzheimer’s disease and primary open-angle glaucoma – Paul A. Knepper, Nicholas Pfahler, Jack McGuire, Indre Bielskus, Michael Giovingo, Nicholas Volpe

Proteins in perfused and non-perfused areas of the trabecular meshwork: potential drug candidates – Julia A. Staverosky, Ted S. Acott, Janice A. Vranka

Modulation of intraocular pressure by ATP sensitive potassium channel openers – Uttio Roy Chowdhury, Peter I. Dosa and Michael P. Fautsch

Development of the nitric oxide donating prostaglandin analog latanoprostene bunod, a novel intraocular pressure lowering drug – Megan E. Cavet, Jason L. Vittitow

Targeting the adenosine A receptor in the eye with trabodenoson, an adenosine mimetic – Cadmus C. Rich, David S. Albers, James A. Gow, Rudolf A. Baumgartner

Lasers

Laser trabeculoplasty renewed – Stephen S. Bylsma, Ted S. Acott, Mary J. Kelley, John R. Samples

Micropulse cyclophotocoagulation: an update on a novel glaucoma treatment – Krishna B. Patel, Elizabeth A. Martin, Mitchell J. Greenberg, Thomas D. Patrianakos, John R. Samples, Paul A. Knepper, Michael C. Giovingo

Panmacular subthreshold diode micropulse laser (SDM) as neuroprotective therapy in primary open angle glaucoma – Jeffrey K Luttrull, John Samples, David Kent, Bryant J. Lum

Surgery: Theoretical consioderacions

The development of SIBS and the InnFocus MicroShunt® – Leonard Pinchuk, Isabelle Riss, Juan F. Batlle, Yasushi P. Kato, John B. Martin, Esdras Arrieta, Paul Palmberg, Richard K. Parrish, II, Yongmoon Kwon, Jean-Marie Parel

What is the ideal conjunctival bleb? Learning from minimally invasive glaucoma filtration surgery – Dao-Yi Yu, Stephen John Cringle, William H. Morgan, Er-Ning Su

Trabecular Meshwork Study Club Abstracts

Glaucoma Research and Clinical Advances

Volume 2 - 2018 to 2020

Kugler Publications